Business Context and Reporting Period
This Form 8-K Current Report was filed by Vanda Pharmaceuticals Inc. on October 28, 2019, regarding an event that occurred on October 22, 2019. The filing pertains to corporate governance changes, specifically the election of a new director to the Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel and compensation arrangements.
Material Changes
- Board Composition: The Board of Directors increased the number of directors from five to six.
- New Director Election: Anne Sempowski Ward was elected as a director, effective October 28, 2019. Her initial term expires at the 2020 annual meeting of stockholders.
- Independence: The Board determined that Ms. Ward qualifies as an independent director under SEC and Nasdaq rules.
Compensation and Governance Details
In connection with her election, Ms. Ward received the following compensatory arrangements:
- Initial Stock Option: An option to purchase 35,000 shares of common stock at an exercise price of $14.21 per share (closing price on October 28, 2019).
- Vesting Schedule: 25% vests after one year of continuous service; the remaining 75% vests in equal monthly installments over the subsequent three years.
- Annual Fee: A $45,000 annual fee, payable quarterly.
- Future Awards: Eligibility for an annual option to purchase 10,000 shares and a restricted stock unit award for 5,000 shares upon the conclusion of each annual meeting starting in 2020. These vest one year from the grant date.
- Change of Control: All options and restricted stock units accelerate to 100% vesting in the event of a change of control.
- Indemnification: Ms. Ward entered into an indemnification agreement with the Company, consistent with agreements held by other directors and executive officers.
Investor Verification Checklist
- Verify the impact of the increased board size on future governance decisions.
- Review the full text of the press release (Exhibit 99.1) for additional context on Ms. Ward's strategic value.
- Monitor the upcoming 2020 Definitive Proxy Statement for a detailed description of the outside director compensation program.
- Confirm the vesting status of the initial 35,000 share option in future filings.